Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Autoimmunity

Interferon α or β: which is the culprit in autoimmune disease?

Nature Reviews Rheumatology volume 12, pages 439–440 (2016)Cite this article

Subjects

Type I interferons contribute to the pathogenesis of several autoimmune diseases, with each interferon being preferentially produced in different settings by different cells. Could knowing which one is predominant in a given disease — or patient — lead to better therapies?

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Proposed roles for IFNα and IFNβ in systemic lupus erythematosus (SLE) pathogenesis.

References

  1. Crow, M. K. Type I interferon in the pathogenesis of lupus. J. Immunol. 192, 5459–5468 (2014).

    Article  CAS  Google Scholar 

  2. Higgs, B. W. et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70, 2029–2036 (2011).

    Article  CAS  Google Scholar 

  3. Piehler, J. et al. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 250, 317–334 (2012).

    Article  Google Scholar 

  4. Yao, Y. et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum. Genomics Proteomics 2009, 374312 (2009).

    PubMed  PubMed Central  Google Scholar 

  5. Wong, D. et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS ONE 7, e29161 (2012).

    Article  CAS  Google Scholar 

  6. Khamashta, M. et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-208562 (2016).

  7. Chiche, L. et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 66, 1583–1595 (2014).

    Article  CAS  Google Scholar 

  8. Der, S. D. et al. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623–15628 (1998).

    Article  CAS  Google Scholar 

  9. de Jong, T. D. et al. Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases. Arthritis Res. Ther. 18, 49 (2016).

    Article  Google Scholar 

  10. Baccala, R. et al. Type I interferon is a therapeutic target for virus-induced lethal vascular damage. Proc. Natl Acad. Sci. USA 111, 8925–8930 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. USA and at the Rheumatology Division, Department of Medicine, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, New York 10021, Weill Cornell Medical College, Hospital for Special Surgery, 535 East 70th Street, New York, New York, 10021, USA.,

    Mary K. Crow

Authors
  1. Mary K. Crow
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Mary K. Crow.

Ethics declarations

Competing interests

M.K.C. declares that she has acted as a consultant for Astra-Zeneca, BMS, Lilly, MedImmune, Neovacs, Novartis and Roche.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crow, M. Interferon α or β: which is the culprit in autoimmune disease?. Nat Rev Rheumatol 12, 439–440 (2016). https://doi.org/10.1038/nrrheum.2016.117

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrrheum.2016.117

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing